DelveInsight’s “Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of chronic spontaneous urticaria, historical and forecasted epidemiology, as well as the chronic spontaneous urticaria market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Key Takeaways from the Chronic Spontaneous Urticaria Market Report

• As per DelveInsight analysis, type-specific cases of chronic urticaria included chronic spontaneous urticaria and chronic inducible urticaria, which accounted for approximately 2,811,068 and 1,343,166 cases, respectively, in 2022, in the 7MM. These cases are expected to increase during the study period (2019–2032).
• In 2022, the total diagnosed prevalent cases of chronic urticaria were estimated to be approximately 4,154,234 cases in the 7MM. These cases are expected to decrease by 2032.
• The increase in Chronic Spontaneous Urticaria Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Chronic Spontaneous Urticaria Market is anticipated to witness growth at a considerable CAGR.
• The leading Chronic Spontaneous Urticaria Companies working in the market include Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
• Promising Chronic Spontaneous Urticaria therapies in the various stages of development include Ligelizumab, Omalizumab, QGE031, LOU064, and others.
• March 2024:- Novartis Pharmaceuticals- The purpose of this study was to evaluate the safety and efficacy of ligelizumab in adult Japanese subjects with CSU, who remain symptomatic despite treatment with H1-antihistamines (AHs) at locally approved doses. The study population consisted of 66 male and female subjects aged ≥ 18 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-AH.

 

Discover which therapies are expected to grab the Chronic Spontaneous Urticaria Market Share @ Chronic Spontaneous Urticaria Market Outlook

 

Chronic Spontaneous Urticaria Overview

Chronic Spontaneous Urticaria (CSU), also known as chronic idiopathic urticaria, is a skin condition characterized by the recurrent appearance of hives (also called urticaria) that last for six weeks or more. These hives are typically raised, red or skin-colored welts that cause itching and discomfort. “Chronic” indicates that the condition persists for a prolonged period, and “spontaneous” means that the hives can appear without a specific trigger or cause being identified. It can significantly impact a person’s quality of life due to the itching, discomfort, and potential for social embarrassment. Treatment options usually involve antihistamines and other medications to manage symptoms and reduce inflammation.

 

Chronic Spontaneous Urticaria Epidemiology Insights

The epidemiology section of Chronic Spontaneous Urticaria offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

 

Download the report to understand which factors are driving Chronic Spontaneous Urticaria Epidemiology trends @ Chronic Spontaneous Urticaria Epidemiological Insights

 

Chronic Spontaneous Urticaria Marketed Drugs

• XOLAIR (omalizumab): Roche/Novartis

XOLAIR (omalizumab) is a recombinant DNA-derived humanized IgG1? monoclonal antibody that selectively binds to human IgE. It is produced by a Chinese hamster ovary (CHO) cell suspension culture in a nutrient medium that may contain the antibiotic gentamicin; gentamicin is not detectable in the final product. Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (FceRI) on cells down-regulate. Also, the mechanism by which these effects of omalizumab result in an improvement of CIU symptoms is unknown. In December 2018, Novartis announced that the EC had approved XOLAIR (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with chronic spontaneous urticaria to administer their treatment.

 

Chronic Spontaneous Urticaria Emerging Drugs

• DUPIXENT (dupilumab): Sanofi/Regeneron
• Remibrutinib (LOU064): Novartis Pharmaceuticals
• Lirentelimab (AK002): Allakos/BioWa

 

To learn more about Chronic Spontaneous Urticaria treatment guidelines, visit @ Chronic Spontaneous Urticaria Treatment Market Landscape

 

Chronic Spontaneous Urticaria Market Outlook

Chronic spontaneous urticaria is a disturbing allergic condition of the skin where symptoms persist for more than 6 weeks. A mast cell-driven disease is characterized by recurrent itchy wheals (hives) that may accompany angioedema. It often causes huge socio-economic distress for the patients, significantly impacting their quality of life. Treating chronic spontaneous urticaria is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a stepwise approach, starting with first-line treatments and progressing to more advanced options if necessary.

 

Chronic Spontaneous Urticaria Drugs Uptake

This section focuses on the uptake rate of potential Chronic Spontaneous Urticaria drugs expected to be launched in the market during 2019–2032. For example, Novartis Pharmaceuticals’ remibrutinib (LOU064), a BTK inhibitor, is expected to enter the US market by 2025 and is projected to have a slow uptake during the forecast period.

 

Chronic Spontaneous Urticaria Companies

Chronic spontaneous Urticaria companies working in the market are developing drugs which will drive the market in the upcoming years. Sanofi/Regeneron’s DUPIXENT (dupilumab), Novartis Pharmaceuticals’ remibrutinib (LOU064), AstraZeneca’s FASENRA (benralizumab), Allakos/BioWa’s lirentelimab (AK002), and AstraZeneca/Amgen’s TEZSPIRE (tezepelumab), and others are expected to boost the market.

 

Learn more about the FDA-approved drugs for Chronic Spontaneous Urticaria @ Drugs for Chronic Spontaneous Urticaria Treatment

 

Scope of the Chronic Spontaneous Urticaria Market Report

• Coverage- 7MM
• Chronic Spontaneous Urticaria Companies- Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others
• Chronic Spontaneous Urticaria Therapies- Ligelizumab, Omalizumab, QGE031, LOU064, and others.
• Chronic Spontaneous Urticaria Market Dynamics: Chronic Spontaneous Urticaria Market Drivers and Barriers
• Chronic Spontaneous Urticaria Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Chronic Spontaneous Urticaria Drugs in development @ Chronic Spontaneous Urticaria Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Chronic Spontaneous Urticaria Market Overview at a Glance

4. Methodology of Chronic Spontaneous Urticaria Epidemiology and Market

5. Executive Summary of Chronic Spontaneous Urticaria

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. Chronic Spontaneous Urticaria: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT

15. Unmet needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/